From: Autoimmune diseases and pregnancy: analysis of a series of cases
Drug | FDA category | Permitted during pregnancy | Notes |
---|---|---|---|
Prednisolone | B | Allowed | Associated to medical/obstetric complications (maternal diabetes, preeclampsia, premature rupture of membranes) |
NSAID | B/D | Allowed; avoid from 3rd trimester onward | Risk of premature closure of the arterial duct in the 3rd trimester |
Hydroxychloroquine | C | Allowed | Discontinuation during pregnancy is associated with SLE exacerbations |
Azathioprine | D | Allowed | In the smallest therapeutic dosage, if benefits outweigh risks |
Cyclosporine | C | Allowed | |
Tacrolimus | C | Allowed | |
Sulfasalazine | B | Allowed | |
Methotrexate | X | Discontinue 3–6 months before a planned pregnancy | |
Cyclophosphamide | D | Discontinue at least 3 months before a planned pregnancy | |
Mycophenolatemofetil | D | Discontinue at least 6 weeks before a planned pregnancy | |
Warfarin | D | Discontinue after positive pregnancy test | Can be used while breastfeeding |
LMWH | B | Allowed | Used as primary prevention of thrombotic events during the puerperal period |
IVIG | C | Allowed | |
Rituximab | C | Discontinue at least 6–12 months before a planned pregnancy | |
Belimumab | C | Discontinue at least 4 months before a planned pregnancy |